Tag: AVF

Comparing and contrasting surgically-created AVFs with those made by endovascular means

 Nicholas Inston (Birmingham, UK) tells Vascular News at LINC 2019 about the exciting field of percutaneous arteriovenous fistula (AVF) creation, the main devices and...

Flow Forward Medical exceeds US$8 million investments, awarded grant from NIH

Flow Forward Medical, a medical device company focused on improving outcomes for haemodialysis patients through the rapid creation of high-quality vascular access sites, has...

Meta-analysis shows positive experience for patients who received an endovascular arteriovenous...

An international meta-analysis of clinical experience in patients who received an endovascular arteriovenous fistula (endoAVF) for haemodialysis access was presented at Leipzig Interventional Course...

TVA Medical receives CE mark for everlinQ 4 endovascular AVF system

TVA Medical’s everlinQ 4 endovascular arteriovenous fistula (AVF) system has received CE mark in the European Union. The technology uses a 4F catheter system...

Twelve-month NEAT trial data promising for everlinQ endoAVF haemodialysis access system

TVA Medical has announced the online publication of positive results from the Novel Endovascular Access Trial (NEAT) evaluating its everlinQ endoAVF system. The 12-month...
SAVE-US trial

Bluegrass Vascular announces strategic relationship with Merit Medical

Bluegrass Vascular Technologies is entering into a strategic relationship with Merit Medical Systems. The agreement will streamline European distribution of the recently CE mark-approved Surfacer Inside-Out...

Promising early results for Lutonix US IDE trial in obstructed AV...

The first US randomised controlled trial for drug-coated balloon use for arteriovenous fistula obstructions for 50 years, the Lutonix (Bard) IDE trial was a...
VasQ

VasQ series at Berlin’s Charité University Hospital produces “exceptionally promising results”

As part of the main scientific programme at Dreiländertagung 2016 (4–8 October, Bern Switzerland), Peter Olschewski has reported “exceptionally promising results” from the first...